New inhaled drug aims to stop lung infections in vulnerable blood cancer patients
Disease control
Recruiting now
This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers or who have had a stem cell transplant and have a viral lung infection. Participants receive either the drug or a placebo three times over six days. The goal is to see if PUL-042 can red…
Phase: PHASE2 • Sponsor: Pulmotect, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC